![Tassos Konstantinou](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tassos Konstantinou
Direttore/Membro del Consiglio presso Oxford Biotrans Ltd.
Profilo
Tassos Konstantinou is currently a Non-Executive Director at Oxford Biotrans Ltd.
and a Director at Kynos Therapeutics Ltd.
He previously held positions as a Director at Oxular Ltd.
and STORM Therapeutics Ltd.
Konstantinou holds a doctorate from the University of Oxford and a graduate degree from The University of Chicago.
Posizioni attive di Tassos Konstantinou
Società | Posizione | Inizio |
---|---|---|
Oxford Biotrans Ltd.
![]() Oxford Biotrans Ltd. Chemicals: Major DiversifiedProcess Industries Oxford Biotrans Ltd. develops and commercializes enzymatic process technologies that produce chemical compounds. The firm produces chemicals using ‘green’ biotransformation technology to starting materials into initial focus is on flavors and fragrances using its proprietary understanding of P450 enzyme catalyst technology. The company was founded by Luet Lok Wong in 2013 and is headquartered in Milton Park, the United Kingdom. | Direttore/Membro del Consiglio | - |
Kynos Therapeutics Ltd.
![]() Kynos Therapeutics Ltd. BiotechnologyHealth Technology Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge. | Direttore/Membro del Consiglio | - |
Precedenti posizioni note di Tassos Konstantinou
Società | Posizione | Fine |
---|---|---|
STORM Therapeutics Ltd.
![]() STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Direttore/Membro del Consiglio | - |
Oxular Ltd.
![]() Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Direttore/Membro del Consiglio | - |
Formazione di Tassos Konstantinou
University of Oxford | Doctorate Degree |
The University of Chicago | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Oxular Ltd.
![]() Oxular Ltd. BiotechnologyHealth Technology Oxular Ltd. engages in research and experimental development on biotechnology. The firm develops retinal treatments to access specific small spaces in the eye and to provide drug distribution to tissues involved in retinal diseases. The company was founded by Tom Cavanagh and Ronald K. Yamamoto in 2014 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Oxford Biotrans Ltd.
![]() Oxford Biotrans Ltd. Chemicals: Major DiversifiedProcess Industries Oxford Biotrans Ltd. develops and commercializes enzymatic process technologies that produce chemical compounds. The firm produces chemicals using ‘green’ biotransformation technology to starting materials into initial focus is on flavors and fragrances using its proprietary understanding of P450 enzyme catalyst technology. The company was founded by Luet Lok Wong in 2013 and is headquartered in Milton Park, the United Kingdom. | Process Industries |
STORM Therapeutics Ltd.
![]() STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Kynos Therapeutics Ltd.
![]() Kynos Therapeutics Ltd. BiotechnologyHealth Technology Kynos Therapeutics Ltd. develops medicines for therapies. The company is based in Edinburgh, UK. The British company was founded by Damian Mole, Scott Webster. The CEO is Jonathan R. Savidge. | Health Technology |
- Borsa valori
- Insiders
- Tassos Konstantinou